Alorfi Nasser M, Ashour Ahmed M
Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Diabetes Metab Syndr Obes. 2023 Oct 6;16:3115-3121. doi: 10.2147/DMSO.S430740. eCollection 2023.
Non-alcoholic fatty liver disease (NAFLD) is a predominant health condition across the world due to its rising prevalence and association with various metabolic disorders. Intermittent fasting (IF) has attracted increasing attention as a dietary approach to addressing weight management and enhancing metabolic well-being, and its potential effects on NAFLD have been a topic of growing research interest.
This review aims to critically evaluate the current evidence on IF's impact on NAFLD, including the mechanisms underlying the observed effects in older adults (65+).
A comprehensive search of Clinicaltrials.gov was conducted to identify relevant studies that investigated the effects of IF on NAFLD in older adults (65+). Data on study design, sample size, intervention details, and outcomes related to NAFLD were extracted and analyzed.
As of April 12th, 2023, there were 1304 clinical trials on NAFLD. Most of these were interventional studies. The investigation focused on completed studies and found that limited clinical trials were identified with limited interventional measures. Only five out of the 1304 studies on NAFLD involved IF. Basic and advanced outcome measures were examined.
Although some studies suggest that IF may have potential benefits for NAFLD, the evidence is still limited and inconclusive.
非酒精性脂肪性肝病（NAFLD）在全球范围内是一种主要的健康状况，因其患病率不断上升以及与各种代谢紊乱相关。间歇性禁食（IF）作为一种解决体重管理和促进代谢健康的饮食方法，已引起越来越多的关注，其对NAFLD的潜在影响一直是研究兴趣日益浓厚的主题。
本综述旨在批判性地评估关于间歇性禁食对NAFLD影响的现有证据，包括在老年人（65岁及以上）中观察到的影响的潜在机制。
对Clinicaltrials.gov进行了全面搜索，以确定调查间歇性禁食对老年人（65岁及以上）NAFLD影响的相关研究。提取并分析了有关研究设计、样本量、干预细节以及与NAFLD相关结果的数据。
截至2023年4月12日，有1304项关于NAFLD的临床试验。其中大多数是干预性研究。调查集中在已完成的研究上，发现确定的临床试验有限，干预措施也有限。在1304项关于NAFLD的研究中，只有五项涉及间歇性禁食。对基本和高级结局指标进行了检查。
尽管一些研究表明间歇性禁食可能对NAFLD有潜在益处，但证据仍然有限且尚无定论。
